STOCK TITAN
  1. Home
  2. News
  3. ELDN

Eledon Pharmaceuticals Inc - ELDN STOCK NEWS

Welcome to our dedicated news page for Eledon Pharmaceuticals (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eledon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eledon Pharmaceuticals's position in the market.

News
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. enrolled 12 participants in Phase 2 BESTOW trial for tegoprubart in kidney rejection prevention. Positive Phase 1b data showed safety, efficacy, and improved kidney function. Financially, the company reported a net loss reduction in Q4 2023 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
earnings
-
News
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (ELDN) announced the enrollment of the 12th participant in the Phase 2 BESTOW trial comparing tegoprubart with tacrolimus for kidney transplant rejection prevention. The trial progress indicates a demand for new immunosuppressive options due to the risks associated with current therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
clinical trial
-
News
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Rhea-AI Summary
Eledon Pharmaceuticals successfully completes historic kidney xenotransplantation procedure using tegoprubart, demonstrating safety and efficacy in preventing rejection. Tegoprubart shows potential as a new immunosuppressive option for transplant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.24%
Tags
none
News
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. granted 42,500 RSUs and stock options to an employee, following Nasdaq rules. The RSUs vest in one year, while the stock options vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
News
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Rhea-AI Summary
Eledon Pharmaceuticals, ticker symbol ELDN, announced updated data from the Phase 1b trial demonstrating the success of tegoprubart in preventing kidney transplant rejection. The company also dosed the first participants in the Phase 2 BESTOW trial and achieved significant financing milestones. Eledon aims to complete the Phase 2 BESTOW trial and dose the first islet cell transplant participant for the treatment of type 1 diabetes in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
News
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) granted 921,000 stock options to new Chief Medical Officer, Eliezer Katz, M.D., at a per share exercise price of $1.14. The options have a ten-year term and vest over four years, with both time-based and performance-based criteria tied to patient enrollment milestones in Phase 1b and Phase 2 kidney transplant clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
News
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) CEO, Dr. David-Alexandre C. Gros, to present company overview and participate in panel discussion at NobleCon19 - Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on December 4, 2023. Webcast available on company website and NobleCon website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences acquisition
-
News
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) reported updated data from ongoing Phase 1b trial supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy. The Phase 2 BESTOW trial has also been initiated. The company also reviewed recent business highlights and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
earnings
-
News
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) to present company overview at Jefferies London Healthcare Conference. CEO David-Alexandre C. Gros, M.D. to speak on November 16, 2023, at 8:00 a.m. GMT. Webcast registration available. Webcast replay accessible on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
conferences
News
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Rhea-AI Summary
Eledon Pharmaceuticals reports positive results from Phase 1b trial of tegoprubart in kidney transplant patients. The drug demonstrated safety, tolerability, and potential to protect organ function. No cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection were reported. Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
clinical trial
Stock ELDN logo
Eledon Pharmaceuticals Inc

Nasdaq:ELDN

ELDN Rankings

#4702 Ranked by Market Cap
#4046 Ranked by Stock Gains
N/A Ranked by Dividends

ELDN Stock Data

41.93M
18.02M
5.43%
38.76%
0.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Irvine

About ELDN

eledon pharmaceuticals, inc. is a clinical stage biotechnology company using its expertise in targeting the cd40l pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. our lead program, at-1501, is a potential best-in-class humanized igg1 anti-cd40l antibody with high affinity for cd40l, a well-validated biological target with broad therapeutic potential. the cd40/cd40l pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.